Romulus K. Brazzell

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Durham, NC
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Mary Reumuth, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Romulus K. Brazzell

Form 4 holding Head of Research and Development and Chief Medical Officer

KALA BIO, Inc.

Security class
Common Stock
Shares / value
35,952
Estimated value
$73,701
Report date
22 Oct 2025
Price
$2.05
Ownership
Direct
Form 4 holding Head of Research and Development and Chief Medical Officer

KALA BIO, Inc.

Security class
Stock Option (right to buy)
Shares / value
45,200
Estimated value
Report date
06 Jan 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Romulus K. Brazzell

4 KALA

KALA BIO, Inc.

Report period
22 Oct 2025
Transactions
1
Transaction value
-$38,801
Accepted by SEC
24 Oct 2025, 20:00
Role
Head of Research and Development and Chief Medical Officer
Next action
Open filing details
4 KALA

KALA BIO, Inc.

Report period
24 Jun 2025
Transactions
1
Transaction value
-$21,057
Accepted by SEC
26 Jun 2025, 20:00
Role
Head of Research and Development and Chief Medical Officer
Next action
Open filing details
4 KALA

KALA BIO, Inc.

Report period
03 Jun 2025
Transactions
1
Transaction value
-$13,789
Accepted by SEC
04 Jun 2025, 20:00
Role
Head of Research and Development and Chief Medical Officer
Next action
Open filing details
4 KALA

KALA BIO, Inc.

Report period
26 Jun 2024
Transactions
1
Transaction value
-$26,073
Accepted by SEC
27 Jun 2024, 20:00
Role
Head of Research and Development and Chief Medical Officer
Next action
Open filing details
4 KALA

KALA BIO, Inc.

Report period
31 May 2024
Transactions
1
Transaction value
-$12,192
Accepted by SEC
03 Jun 2024, 20:00
Role
Head of Research and Development and Chief Medical Officer
Next action
Open filing details
4 KALA

KALA BIO, Inc.

Report period
04 Jan 2024
Transactions
3
Transaction value
-$10,899
Accepted by SEC
05 Jan 2024, 16:05
Role
Head of Research and Development and Chief Medical Officer
Next action
Open filing details
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .